Objectives the cytokine profile research in patients with posttraumatic synovitis during intravenous and intra-articular ozone therapy. Material and methods.The research involved 69 patients with traumatic knee joint damage complicated by posttraumatic synovitis. Patients in Group I (35 people) received a traditional treatment. Patients in Group II (34 people) along with the traditional therapy had intravenous injection of 200 ml of ozonated solution of sodium chloride in ozone concentration 2 mg/l once daily for 10 days, and intra-articular injection of 20 ml ozone-oxygen mixture in ozone concentration of 15 mg/l once every second day, in an amount of 5 injections. During arthroscopy, the lavage of the joint cavity was performed with ozonated saline solution at a concentration of 2.0 mg/l. The cytokine profile was evaluated by the content of pro-inflammatory cytokines (TNF-, IL-1, IL-6, IL-17), regulatory (IL-2), IL-1 receptor antagonist, and anti-inflammatory (IL-4, IL-10) cytokines by solid-phase enzyme immunoassay with peroxidase as an indicator. Statistical analysis of the results was carried out using the Student t-test. Results.The use of intravenous and intra-articular ozone therapy contributed to synchronous decrease of the levels of pro-inflammatory cytokines with simultaneous reduction of anti-inflammatory mediators of inflammation. TNF-content decreased by 24.6% (p20.001), IL-17 by 17.3% (p20.01), IL-6 by 20.1% (p20.001), IL-1 by 19.1% (p20.001), IL-2 by 25.7% (p20.001), IL-1RА by 24.4% (p20.001), IL-10 by 21.3%(p20.001), IL-4 by 25.7% (p20.001) in comparison to traditional treatment. Conclusion.The complex ozone therapy led to the decrease of inflammation, which was reflected in the depression dynamics of the studied cytokines. These results allow us to evaluate it as an effective treatment method for post-traumatic synovitis which effectively reduces the secondary posttraumatic alteration of tissue structures.
Among the malignant neoplasms of the hepatobiliary zone, gallbladder cancer (GBC) is rare. The incidence of GBC is highest in patients over 65 years of age. In the early stages GBC rarely has clinical manifestations, and often occurs under the guise of other gastroenterological diseases, and is often an accidental finding. Since GBC tends to show high dissemination, at the time of diagnosis, almost every second patient has an advanced form of the disease that is not the subject to surgical treatment. Most authors tend to believe that the use of combined treatment of GBC (extended resection and adjuvant chemotherapy) significantly increases the survival rate of patients. Currently, about 1/3 of patients receive adjuvant chemotherapy in the treatment of GBC. This is due to a small number of prospective randomized trials. Today, most experts recognize that surgery is the only treatment that can be performed in patients with early stages of prostate cancer. At the same time, a reduction in the risk of complications and a large percentage of five- and ten-year survival are achieved. Traditional cholecystectomy can be used to treat stage 1a PCa, this is possible if PC is accidentally found during surgical treatment of GSD. Unfortunately, prostate cancer and bile ducts belongs to the group of malignant neoplasms, in which most patients are unable to perform radical surgical treatment due to for the rapid dissemination of the process. When determining the tactics of patient supervision, it is necessary to take into account the prognostic factors of overall survival in prostate cancer: the type of surgery, the patient's age and sex, the size of the tumor, the presence of metastases in the regional lymph nodes, the presence of adjuvant chemotherapy. There is still a dispute between specialists about the appointment of adjuvanted chemotherapy to patients after surgical treatment of prostate cancer. Many authors acknowledge that adjuvant chemotherapy plays a positive role in improving patient survival after surgery. RAD is recognized as a chemosensitive cancer. Several drugs are active in relation to RS, used for adjuvant chemotherapy: fluorouracil, gemcitabine, mitomycin, cisplatin, capecitabine, epirubicin, and oxaliplatin. This article provides an overview of current research that is aimed at studying the effectiveness of adjuvant chemotherapy in patients with verified GBC of various stages.
Информация о финансировании. Финансирование данной работы не проводилось. Конфликт интересов. Авторы заявляют об отсутствии конфликта интересов.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.